CD274 and neoplasm: The anti-CTLA-4 agent Ipilimumab induced ADA upregulation in 5.4% of patients [160], while the anti-PD-L1 Durvalumab induced such an upregulation in 2.9% [161] of patients; the higher levels of ADA (13–54% of patients, with NAb in 4–28% of the cases) have been reported in patients treated with Atezolizumab plus Bevacizumab at different doses and regardless of tumor histology [162].